Mirum Pharmaceuticals Inc

NASDAQ:MIRMUnited States

May 18, 2024

Show headlines and story abstract

• Mirum Pharmaceuticals' LIVMARLI Data Showcased at ESPGHAN Annual Meeting, from 7:00AM ET on Saturday May 18, 2024 by Business Wire

  7:00AM ET on Saturday May 18, 2024 by Business Wire
  Companies Mentioned: MIRM

  --- Long-term extension data from Phase 3 MARCH-ON PFIC study presented at plenary session and selected among the highest scoring abstracts

  Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today announced data presented during the 56th European Society for Paediatric, Gastroenterology, Hepatology, and Nutrition (ESPGHAN) Annual Meeting which took place this week in Milan, Italy. Data from LIVMARLI(R) (maralixibat) oral solution clinical studies and real-world settings in Alagille syndrome (ALGS) and Progressive Familial Intrahepatic Cholestasis (PFIC) were presented in oral and poster presentations during the meeting.

• Mirum Pharmaceuticals' LIVMARLI Data Showcased at ESPGHAN Annual Meeting, from 7:00AM ET on Saturday May 18, 2024 by Dow Jones

  7:00AM ET on Saturday May 18, 2024 by Dow Jones
  Companies Mentioned: MIRM
  
  This press release includes forward-looking statements pertaining to the Company's planned participation at a scientific conference, including data presentation title and synopsis, which may include discussion of the Company's clinical and research data relating to the therapeutic potential and/or commercial viability of LIVMARLI in various liver disease indications and in patient populations that are investigational only. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Words such as "will," "goal," "potential" and similar expressions are intended to identify forward-looking statements. The accuracy of such statements is subject to a number of risks, uncertainties and assumptions including, but are not limited to, the following factors: the uncertainties inherent in research and development; the uncertainties inherent in business and financial planning, including, without limitation, risks related to Mirum's business and prospects, adverse developments in our focused markets, or adverse developments in the U.S. or global regulatory environment or economies generally; the continued impact of COVID-19 on our business, operations and financial results; and competitive developments. Other factors that might cause such a difference include those discussed in the Company's filings with the SEC. All forward-looking statements contained in this press release speak only as of the date on which they were made and are based on management's assumptions and estimates as of such date. Mirum undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made, except as required by law.